On January 3, 2025, an expert team including Ge Jianli, a director of Chengda Pharmaceutical, Lu Gang, the general manager, Dr. Liu Shiling, the deputy dean of the research institute, Deng Xiaogang, the R & D director, and Han Jianlong, a senior manager of Everbright Securities, visited our company (MoMed Biotech). They had in-depth technical exchanges with Bai Chen, the chairman of MoMed Biotech, and explored more possibilities for cooperation between traditional medicine and AI-based new drug research and development.

On January 3, 2025, an expert team consisting of Ge Jianli, a director of Chengda Pharmaceutical, Lu Gang, the general manager, Dr. Liu Shiling, the deputy dean of the research institute, Deng Xiaogang, the R & D director, and Han Jianlong, a senior manager of Everbright Securities, visited MoMed Biotech for exchanges and guidance. Bai Chen, the chairman of MoMed Biotech, together with Zhu Xiaohong, the R & D director, An Ke, the operation director, and Li Zhen, the project manager, gave them a warm reception.

Led by Bai Chen, the chairman of MoMed Biotech, the team from Chengda Pharmaceutical briefly visited the company's R & D computer rooms and work areas, and got a preliminary feel for the scientific research atmosphere there.

     Subsequently, the two sides held discussions and exchanges. Firstly, they focused on the cutting-edge hotspots in the industry and conducted in-depth discussions. As a pharmaceutical enterprise that has been deeply involved in the traditional pharmaceutical field for many years, Chengda Pharmaceutical expressed its approval for the scientific research strength of MoMed Biotech, which has been constantly exploring new drug research and development empowered by AI.      

     During the exchange process, both sides keenly perceived the huge potential for complementary cooperation between them. Immediately afterwards, they carried out in-depth discussions around the diverse possibilities of future cooperation and put forward a variety of cooperation proposals for the key areas and suitable models where they could work together.      

     Everyone unanimously hoped that by virtue of their respective expertise and resources, they could spark inspiration in key areas such as chemical pharmaceuticals and the research and development of biologic innovative drugs, jointly overcome difficulties in the industry, jointly explore a broader market space, and inject new impetus into the vigorous development of the pharmaceutical industry.